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Pros tacycl in (PG I2) and PGE2, the predominant cycloox-
ygenase products of endothelial cell s are po tent vasodila-
to rs. An in ability to produce appropriate concentrations of 
th ese pros tanoids may be a facto r in the pathogenes is of 
the digital vasos pas m ex peri enced by patients w ith Ray-
n a ud 's pheno menon (RP). The effect of sera from norm al 
subjects, patients w ith primary RP , and patients with RP 
in association w ith sys temic sclerosis (SS) on the produc-
tion of PG I2 and PGE2 by cultured hum an endotheli al cell s 
was in ves tigated. All se ra produced a dose-dependent in-
hibition of 6-keto-PGF, cr , but both the 10% and 20% sera 
fro m patients with RP and SS produced a signifi cantl y 
g reater inhibitio n than control sera. The mean production 
of 6-keto-PGF ,cr ex pressed in ngl1 04 cells was 2.278 (nor-
R aynaud 's phcnomcnon (RP) is characterizcd by epi-sodi c dig ital vasos pastic ischemia in res po nse to co ld o r cm otio nal stress 1"1 J. The cause is no t known but the re are suggcstions th at an altered scnsiti vity to o r defective produ ctl on o f vasoactl ve mcd lators ma y be 
of pathoph ysio logic signifi ca nce. Prostacyclin (PG I2), a potent 
vasodil ator and inhibi tor of p late let aggrcga tio n is the predo mi-
nan t cy clooxygenase product of arachidoni c acid metabo lism in 
endotheli al cell s fro m artcri es and veins [2]. An imbalance be-
tween PG I2 produ cti on and the rcpo rted raiscd cndogenous bio-
synthes is ofthro mboxane reported in patients w ith sys temic sclc-
ros is and Raynaud 's phenomenon [3] m ay exacerbate thc dig ital 
vasos pas m in th cse pati ents. The subj ective and obj ecti ve im-
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A bbreviations: 
BSS: balan ced sa lt so lu tion 
M1 99: medium 199 
PG E2: pros tag landin E2 
PG I2: prostaglandin 12 
HP: Raynaud 's pheno menon 
SEM: sca nning electron microscopy 
SS: sys tcmic scle ros is 
TXB2: thro mboxa ne B2 
ma l), 1. 9311 (RP), and 2.1 824 (SS) after in cubatio n with 
1 % serum for 24 h. This decreased to 1. 3647, 0.5927, and 
0.4171, respecti vely foll owin g in cubation w ith 20% sera 
for 24 h. This rep resented a 44% (no rm al), 76% (RP) , and 
83% (SS) in hibition o f6-keto-PG F, cr production co mpared 
w ith serum free media. Si milar results we re obtained after 
1 h in cubation experim ents. T here was a nonsignifi cant 
decrease in mean PGE2 production followin g simil ar in-
cubations with 1 % and 20% sera for 24 h. T hese results 
sugges t that factor(s) present in the se ra of pati ents w ith 
RP m ay redu ce the abili ty of endo th eli al ce ll s to synthesize 
o r release the vasod il ato r and antiagg regatory pros tanoid 
PG I2 . J IillJ est Del'llJalo/ 89:555-559, 1987 
provcm ent after infusions of PGh [4,5 ] lends furthcr support to 
this theory. Altern ati vely, there Illa y be altered prod uction o r 
secrction of th c other end othelium dcri ved vasoact ive mcd iator , 
PGE2, so we were interested to assess w hether sera from patients 
w ith primary Raynaud's pheno m cnon and patients w ith Ray-
naud 's pheno menon in associati on w ith systemi c sclerosis woul d 
m odify the ability of cultured end o th elial cell s to synth es ize thc 
prostano ids PG I2 and PGE2. 
M ATEH IALS AND METH ODS 
Endothelial Cell Cultures Human umbili ca l vein endothelial 
cells we re grow n in cu lture usin g the m ethod described by J affe 
18]. B rieRy, umbili ca l veins from in d ividu al co rds we rc cannu-
lated , washed w ith balanced sa lt so lu tio n (BSS, pH 7.4) and fi lled 
w ith 0. 1 % co ll agenase (C lostridium Histo lyti cum , Bochrin ger 
Mannh eim G mbH , F.R .G .). After a 12-min in cubation at 37°C, 
dctached ce lls werc obtain ed by Ru shin g with M edium 199 an d 
we re centrifuged at 250 ,Q for S min. The cell pellct was resus-
pended in M 199 containin g 100 units/ml pcni cillin , 50 J.Lg/ml 
strepto m ycin , amphotcricin B, glutamine (Gibco), and 20% pooled 
hum an serum and wcre g rown in 24- well plastic c1ustcr plates 
(Stcrilin Ltd, Fcltham . U.K. ) in humi dified 5% C02/95% air at 
37°C. In all ex perimcnts the cells used we re primary cultures at 
co nRu cnce and they were identifi ed as cndothclial cells by their 
"cobblestone" appca rance and by pos itive uniform sta inin g fo r 
Facto r VIII-related antigen. 
Sera Sera were obtained fro m 13 untreated patients w ith diffu sc 
sys temic scleros is diagnoscd acco rdin g to th e prelim inary criteria 
of the American Rh eum atism Association [9] (4 men , 9 wo men; 
m ea n agc 50, age range 33-70 yea rs), 12 patients w ith primary 
Ibynaud's phcnom enon w ho suffered fro m attacks of RP 
thro ug hout the yea r (12 women; mean age 35, age range 21-52 
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yea'rs), and 9 no rmal contro ls (3 m en, 6 women; m ean age 44, age 
range 23- 65 yea rs). In so me ex perim ents, sera from pati ents w ith 
sys temic sclerosis were subj ected to ultracentrifuga ti on at 100,000 
g fo r 1 h in a Beckm an L265B centrifuge [1 0] to remove immune 
co mplexes from the sera. 
Incubations of Cultured Endothelial Cells With Sera C on-
Aucnt prim ary cultures we re washed once w ith M1 99 and then 
were in cubated w ith either 1, 5, 10, o r 20% se ra from each patient 
fo r bo th 1 and 24 h in humidified 5% CO2/95% air at 37"C. At 
the end of each incubati on the cell s were was hed w ith M1 99 and 
fo ll owin g stimul ation with the calcium iono pho re A23187 10 p.M 
(Sig ma, Poole, D orset, U .K. ) fo r 2 h, the supernatants w ere 
co llec ted and frozen at - 20°C. The end othelial cell s w ere tryp-
sini zed (0.25% tr ypsin ), centrifu ged at 500 g fo r 1 min , resus-
pended in 200 p.1 ofBSS and after addition ofl 0 p.1 ofmeth ylenc 
blue th e ceUs w cre counted in an im pro ved N eubauer C hamber 
(Weber, U.K .). 
Radioimmunoassay of 6-Keto-PGF t a The antibod y to 6-
keto-PG F
'a (donated by Dr M. G rea ves, Departm ent o f Hema-
to logy, Roya l H aUamshire Hospital, Sheffie ld , U .K.) was in cu-
bated w ith the samples overnight at 4°C. C ross reacti vities of the 
antiserum with o ther maj o r eicosanoids (PGE2 , PG F2a , TXB2) 
were less than 1 % . T he tracer was 6-keto-[3H]PG F
'a (Amersham 
International PLC, All1 ersham , U.K. ) and the standard w as 6-
keto-PG F
'a (Well co me Laboratories, Beckenham, U.K.). Un-
bo und tracer w as separated fro m bo und b y the additio n o f dex-
tran/charcoa l. T he assa y was linea r over th e conccntratio n range 
0.1 to 2.5 ng/ ml and th e limit o f scnsitivity w as 39 pg/ ml. 
Radioimmunoassay ofPGE2 The antibod y to PGE2-9- m eth-
yloxime w as donated by Dr R . W. Kell y, MRC Reproducti ve 
Biology Unit , Uni versity of Edinbu rgh, Sco tland [11]. The sam-
ples, the stand ard PGE2 (Sig m a), and th e tracer [3H]PGE 2 (Amcr-
sham) were all m eth yloximated before the assa y . The efti ciency 
or' m ethylox imati on w as g rea ter th an 95% . C ross reactivities of 
the antiserum aga inst PGE,-9-meth yloximine was 28. 7% and 
aga inst arachid oni c acid , 0.05% . The assay was linear o ver the 
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Figure 1. Effect of increas ing concentrations of sera from norm al contro ls 
(circles), patients with primary Raynaud 's phenomenon (trial/gies), patients 
with Raynaud 's phenomenon in association with systemic sclerosis (sqllares) 
on production of 6-keto-PGFla by cultured human umbilical vein endo-
thelial cells. ConAucnt monolayers of ce lls were incubated with 1-20% 
concentrations of serum fo r 24 h at 3rC prior to challenge with 10 p,M 
A23187. Values are expressed as mean ± SEM. The statistical significan ce 
of the responses is indica ted by a * (p < 0.005), ** (p < 0. 01) , and *** 
(p < 0.05). 
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Figure 2. Effect of increasin g conccntr:uions of sera fro m norl11 al controls 
(circles), patients with prim ary Ibynal1d 's phenomenon (sq l/ares) , pa tients 
with Ibynal1d 's phcnomenon in association with sys tcmic sclerosis (tri-
al/gil'S) on production of 6-keto-PGF,o by cultured hum an umbilica l ve in 
endothel ial cells. ConAuent monolayers of cells were incubated with 1-20% 
concentrations of serum fo ri h at 37°C prior to challenge with 10 p,M 
A23187. Values arc expressed as mean ± SEM. The statistical significance 
of the responses is indicated by a * (p < 0.005), ** (p < 0.0 1), and *** 
(p < 0.05) . 
concentrati on range 40 to 1000 pg / ml and th e limit o f sensiti vity 
w as 40 pg/ ml. 
Electron Microscopy C ultured end othelial cell s were g rown 
on T herman ox ti ssue culture cover sli ps (Miles Laboratories, N a-
perville, Illinois) and in cubated w ith 20% sera as above. The cells 
were fi xed in g lutaraldehyde (1 %) in sodium cacod ylate buffer 
(0 .1 M , pH 7.2, 475 mos mol) fo r 1 h and postfi xed fo r 1 h in 
os mium tetroxide (0.5%) . They were deh ydrated in ascending 
eth anol concentrati ons and werc processed fo r scanning electron 
microsco py (SE M ) usin g standard techniques [1 2]. 
Statistical Analysis Differences in pros taglandin produ cti on 
fo llo w in g addition o f sera were anal yzed by co mparing the effect 
of one se rum concentrati on from pati ents with RP o r SS against 
th e sa me concentrati on fro m norm al indi viduals using the 
M ann-Whitney tes t. 
RES ULTS 
6-Keto-PGF ta Production There was a dose-dependent in-
hibition of 6-keto-PG Fla production by sera fro m no rm al con-
tro ls, patients w ith H .aynaud' s phenom enon , and patients w ith 
Raynaud 's phenomenon in association with systemic sclerosis after 
24- and 1-h in cubations (Figs 1, 2). The inhibitio n fro m the latter 
two groups w as g rea ter and the difference fro m th e cont ro ls 
beca me statisti call y signifi ca nt as the concentration of sera was 
in creased to 10% and 20% . Sera fro m patients with sys temic 
scl erosis caused more inhibiti on than sera fro m patients w ith pri-
mary Raynaud's pheno menon in th e 24-h in cubations alth ough 
th e reverse was found in the 1-h in cubations. There was no sig-
nifi ca nt difference between any o f th e valu es o btained w ith sera 
fro m either the systemic sclerosis o r Ray naud 's pheno m enon pa-
tients. The percent inhibiti on o f 6-keto-PG F la production by the 
different sera compared w ith serum free media after a 24-h in-
cubation is show n in Fi g 3. Similar data (no t shown) was o btained 
follow ing a 1-h in cubati on. T o ensure that this inhibition was 
not a res ult o f the sera having stimulated the cell s, thereby causing 
the cells to be refractory to furth er stimul ation by A231 87, levels 
of 6-keto-PGF
'a were m easured in the sera/supern atant after the 
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Figure 3. The effect of increas ing concentrations of sera from no rm al 
Controls (sq llares) , patients with primary Raynaud's pheno menon (rriall-
g les), patients with Raynaud 's phenomenon in associa tion with systemic 
sclerosis (circles) to inhibit 6-keto-PGF,u production. Results are expressed 
as percentage inhibition of serum free media after a 24-h incubation. 
24--h incubation. Levels of this prostanoid were less than 0.4 ngl10" 
cells in ten ex periments using 20% sera from patients with sys-
temiC sclerosis. 
The data in Table I indica te that sera fro m patients with sys-
temic sclerosis subj ected to centrifuga tion at 100,000 g maintained 
the sa me level of inhibitio n as untrea ted sera. T hese res ul ts are 
con sistent with our unpublished observa tions that none of the 
se r a from the patients w ith SS had detectable levels of immune 
complexes using the C 1 q binding assay (data not shown) . 
To exclude the possibility that the effect of the sera was due 
to a llo typic differences between the donors of the umbilica l cords, 
cultures of endothelial cells were derived from single o r several 
pooled donors. T here was no signi fica nt difference in the resu lts 
w h en cells were derived fro m one source o r multiple donors. 
PGEz Production T he concentration of PGE2 in the super-
natants was 10 to 100 tim es smaller than the concentration of 6-
keto-PGF la (Table II ). Increasing the concen tration of sera from 
all p atients cau sed a reduction in PGE2 production, but there was 
no signifi cant di ffe rence between the patient groups. 
Electron Microscopy Examination by SEM showed no rm al 
morpho logy of the endo thelial cells followin g in cubation w ith 
the different sera. T he cells were in close ap positi on to each o ther, 
the re was no disruption of the conflu ent mo nolayer and there 
was no vesiculation or bleb bing of th e cell surface. 
Table I. Effects of Ultracentrifugation of Sera on 
6-keto-PGF la Production 
Patient Group 
Sys temic sclerosis 
1% 
5% 
10% 
20% 
Untreated Se a 
2.1 82 ± 0.356 
1.31/ ± 0.232 
0.752 ± 0.182 
0.4 17 ± 0.166 
Ultracentri fuged Sera 
2.796 ± 0.462 
1. 730 ± 0. 155 
1.017 ± 0.113 
0.575 ± 0.136 
Effect of ultracentrifugat io n of sera (a t 100,000 g for 1 h) from five patients with 
Ra ynaud 's pheno meno n in association with systemic scleros is 0 11 productio n of 
6-keto-PGF 1D by culru rcd hum an lImbi lic:1 1 ve in endothelia l ce ll s. Cells were in-
cubated w ith the va ryin g concentrations of sera fo r 24 h at 37°C prio r to challenge 
w ith IOJLM A23 187. Values arc expressed as mean :!: SEM. T here was no signifi ca nt 
differen ce between th e untreated and ult ra centrifuged sera . 
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Table II. Effects of Sera on PGE2 Production 
Patient Group 
Normal controls (n = 5) 
1° Raynaud's Pheno menon (11 = 8) 
Systemic sclerosis (n = 8) 
1% Sera 
0. 104 ± 0.018 
0. 162 ± 0.023 
0.256 ± 0.072 
20% Sera 
0.077 ± 0.025 
0.077 ± 0.0 18 
0. 10 ± 0.008 
Effcct of 1 % and 20% ser:1 fro l11 110rn1:11 comro ls , patients w ith pr im:u y Ra ynaud's 
pheno menon. patients w ith Ra YJ1aud 's pheno menon in association w ith systemi c 
sclerosis 0 11 prod uctio n ofPGE, by cultured hum an umbili ca l vein endothelial cells . 
Cells were in cubat(."d w ith the v:lrying conccntratio ns for 24 h at 37°C prior to 
cha llenge with A231 87 IOJLM. Va lues arc expressed as mean :!: SEM . T here was 
110 signifi cam differen ce ill PGE2 prod uct ion between the pa tien t groups. 
DISC U SSIO N 
This study has demonstrated that sera fro m both patients with 
pnmary Raynaud 's phenomenon and those w ith systemic scle-
rosis and Raynaud 's pheno menon render cultured human endo-
th eli al cells refractory to furth er stimulation to produce prosta-
cyclin. T hi s may be relevant in the pathogenesis of Raynaud 's 
phenomenon, since a fa ilure to produce prostacyclin would mod-
ulate platelet/vessel wall interactions and disturb the balance be-
tween the th rom boxa ne/vasoconstri ctor and prostacycl in / 
vasod ilator ratios [1 3]. 
Attempts to confirm this imbalance in vivo arc frustrated by 
the fac t that prostacyclin is not a circulating hormone [1 4]. Belch 
and colleagues [15] reported that mean levels of plas ma 6-keto-
PGF l a (the stable metabolite of PGI2) in patients w ith SS and 
Raynaud 's pheno menon were raised at 51 ng/ ml , co mpared with 
11 ng/ml in patients w ith primary Raynaud 's pheno menon and 
16 ng/ml in co ntro ls. T hese es tim ations were ca rried out by ra-
dioimmunoassay and they probabl y suffe red from one o r many 
of the va riables that influence this technique w hen prostaglandins 
are measured in plas ma [1 6]. Ritter [1 7.1, using w hat is believed 
to be the most sensitive and specific assay for 6-oxo-PGF l a (gas 
chro matog raph y/nega tive ion chemica l ionisa tion mass spec-
trom etry) , fo und that plasma levels in hea lth y subj ects are less 
than 5 pg/ m l. Indeed , even intravenous infusio ns of prostacyclin 
that cause vasod ilatation, headaches, and platelet effects produce 
blood levels of on ly 380 pg/ ml [1 8,19]. Another meth od of mea-
surin g prostacyclin is the analysis of the urin ary metabo lite 2,3 -
dinor-6-keto-PGF l a . U sing this assay, Fitzgerald and associates 
reported that th e basal excretion of this metabolite in patients 
with sys temi c sclerosis and Raynaud 's pheno menon (248 ng/g 
crea tinine) was more than double the control values (11 2 ng/g 
crea tinin e) [3]. This findin g lacks disease specificity, sin ce en-
hanced prostacycl in synth esis also was found in patients with 
diffuse atherosclerosis [20] and the levels reported in patients with 
systemic sclerosis were similar to those of controls in another of 
their studies [21 ]. The problcm of measurin g urin ary metabolites 
is that it is onl y an estimated rate of prostacyclin secretion from 
the whole vascul ar trce and the amount of renal contribution to 
the total ca nn ot be measured . In addition , a compensatory in-
creased prostacyclin production by normal endothelium may ob-
scure the decreased produ ction by diseased vessels [22J. Despite 
these reservations , Deray and coworkers [23J recently reported 
that urin ary excretion of 6-keto-PGF l a decreased by about 50% 
in 2 patients with cyclosporin-induced Ra ynaud 's phenomenon. 
This o bservation adds furth er credence to the hypothesis that 
endothelial cell d ys fun ction con tributes to the pathogenesis o fRP 
and analysis of prostacyclin production from arteries or vei ns 
excised fro m patients w ith systemic sclerosis may well resolve 
th is question. 
Although sera fro m th e two groups of patients inhibited pros-
tacyclin production in this study, sera from the controls also had 
a similar but lesser effect . T his findin g cont rasts w ith the reports 
of Ritter and associates [24] and Seid and colleagues [25), w ho 
showed that normal hum an se rum stimulated the production of 
prostacyclin in a dose-dependent manner. In their experim ents , 
however, Ritter used chopped rings of rat aorta, w hereas Seid 
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us'ed porcine ao rti c endo th eli a l ce lls, w hi ch , when in cubated w ith 
the test materi al, were kept unde r constant rotatio n . C ross species 
differen ces be tween the source of of se ra and endotheli a l ce ll s 111 a y 
no t a ll ow ex trapo lat io n to cultured hum an end o th e li a l ce ll s and , 
in addition , th e constant ro tat io n per se w ill stimula te prostacyclin 
producti o n . T h e ca use o f the inhibito ry effec t is not kno w n but 
inte res tingl y ca lf serum alSo h as a re lati ve inhibito ry effect o n 
hum an endothelial cells [26]. 
The maj or p roduct of arachidoni c acid m e tabo lis m in micro-
vascul a r endo th elia l cell s cultured from neona tal foreskin is th e 
vasod ilato r PGEz [27]. Our findin g that cultured hum an umbili ca l 
ve in endothelia l ce lls produced considerabl y less PGE2 than PG lz 
is in accord w ith the data of C haro and coworke rs. In contras t 
to th e red u cti o n in P G lz producti o n fo ll owin g in cu bation w ith 
o ur patients sera there was no s ig nifi ca nt reduction in PGEz pro-
du ction. This ma y h ave res ulted from the radio immunoassay 
bein g un able to d e tec t changes in an a lread y low basal level of 
PGE2 or to th e fac tor(s) present in th e sera bein g m edia tor specifi c. 
V ascul ar d am age is a m ajor fea ture of systemic scle rosis, and 
the extent of vascular in volvem ent is thou g ht to determine the 
ultim ate prognosis [28]. This m ay b e assessed clin ica ll y by ex-
amin ation of the mi crovascula ture of th e nailfo ld cap illary bed 
[29,30] . Recently, s imil a r but less severe abnorm alities have been 
found in primary Rayn aud 's ph en o m en o.n [311. Histopatholog i-
ca ll y, there is intimal h yperpl as ia in both patients wi th primary 
Lbynaud' s phen o m en o n and in those w ith sys temi c sclerosis in 
associati o n with Raynaud 's ph en o m en o n [32,33], but th e ult ra-
s tru ctural abn o rm ali ties of endoth elia l ce ll swell in g, thi ckenin g, 
and red upli cat io n of the basa l lamina, dis tortion of intercellul a r 
junctions, and ac tu al loss o f endotheli a l ce ll s were not found in 
patients w ith prim ary Raynaud 's phenomenon [34,35]. 
C ircul ati n g cytotoxic factors have been reported to be invol ved 
in th e pathogenesis of these ch an g es in systemic scl erosis [36], 
but so m e resea rch ers have been un ab le to confirm these findin gs; 
ot.hers hav e found se rum-med iated endothelia l cyto toxicity in 
other connective ti ssue diseases [37,38]. We conside red th at m ore 
subtle biochemi cal chan ges m ay have preced ed ch an ges in cell 
turnover o r ce ll lys is as m easured b y these invest igators and there-
fore perfo rm ed the present stud y . 
Serum from patients w ith sys te mi c sclerosis appears no t only 
to inhibit prostacycl in production but also to cause increased g row th 
of fibroblasts that h ave hi g h levels of co llagen synth esis [39], to 
suppress the mito geni c ac tivity of ly mphocytes [40], to decrease 
th e fi lte rability of n o rm al e ry throcytes, and to in crease the ad-
heren ce of normal erythrocytes to endothelial cell s [41]. It is known 
th at a number of plate le t release products stimulate endothelia l 
PGlz re lease, includin g th e adenine nucleo tides ADP an d AT P 
[42], pl atelet-derived g ro wth fac to r [43], pl a tel e t ac ti va ting facto r 
[44], and serotonin [45] . Perhaps the serum facto r in o ur patients 
with Raynaud 's ph enom enon prevents this physio log ic response 
to in creased plate let ac tiva tio n [46] . We believe that isolation of 
this facto r(s) may help unravel the p athogenes is of Raynaud's 
phenom eno n and perhaps eliminatio n of these may acco unt for 
the clinical and h em o rrheolog ic improve m en t o bserved follow-
in g p las m a exchan ge [47-49] . 
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